Pain Specialists of Cincinnati, LLC
Pain Specialists of Cincinnati, LLC was paid $4.61M by Medicaid between Jan 2018 and Dec 2024, across 119 billing codes. Its largest line is 99214, doctor's office visit, returning patient (more involved) — 21% of everything it billed.
33Billing provider infoPAIN SPECIALISTS OF CINCINNATI, LLC
CINCINNATI, OH 45248
CINCINNATI, OH 45248
33aNPI1558740282assigned 05/27/2015
33bProvider typeChiropractor
28Total paid$4.61M
24GClaims194,494
24DCodes billed119
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Chiropractor providers in Ohio
Rank by total paid#1 of 664
Median peer was paid$24K
This provider vs. median193×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 34,775 | $528K | |
| 2019 | 51,889 | $805K | |
| 2020 | 47,622 | $926K | |
| 2021 | 19,939 | $753K | |
| 2022 | 13,156 | $557K | |
| 2023 | 12,589 | $531K | |
| 2024incomplete | 14,524 | $509K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 21% | 20,462 | 17,974 | $968K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 12% | 15,527 | 13,777 | $535K |
| G0482 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed | 10% | 4,885 | 4,465 | $471K |
| G0481 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed | 7.0% | 3,809 | 3,513 | $320K |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 4.3% | 8,175 | 7,301 | $198K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 2.8% | 5,049 | 1,839 | $127K |
| 62323 | 2.6% | 943 | 852 | $122K | |
| 27096 | 2.4% | 1,196 | 980 | $111K | |
| 93923 | 2.4% | 827 | 775 | $109K | |
| 20611 | 2.1% | 2,115 | 1,734 | $98K | |
| 99204 | Doctor's office visit, new patient (more involved)Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity | 1.6% | 1,143 | 1,101 | $74K |
| 80346 | 1.6% | 3,455 | 3,059 | $73K |
107 more codes
| 80361 | 1.4% | 3,677 | $67K | |
| 95923 | 1.3% | 1,745 | $62K | |
| 64450 | 1.3% | 806 | $60K | |
| 95924 | 1.3% | 1,102 | $59K | |
| L0637 | Lumbar-sacral orthosis, sagittal-coronal control, with rigid anterior and posterior frame/panels, posterior extends from sacrococcygeal junction to t-9 vertebra, lateral strength provided by rigid lateral frame/panels, produces intracavitary pressure to reduce load on intervertebral discs, includes straps, closures, may include padding, shoulder straps, pendulous abdomen design, prefabricated item that has been trimmed, bent, molded, assembled, or otherwise customized to fit a specific patient by an individual with expertise | 1.1% | 71 | $53K |
| 80362 | <1% | 2,464 | $46K | |
| 76942 | <1% | 1,065 | $39K | |
| 80365 | <1% | 3,688 | $37K | |
| 80348 | <1% | 3,673 | $37K | |
| 80349 | <1% | 3,658 | $37K | |
| 80353 | <1% | 3,669 | $37K | |
| 80358 | <1% | 3,657 | $36K | |
| 80356 | <1% | 3,656 | $36K | |
| 83992 | <1% | 2,468 | $36K | |
| 80360 | <1% | 3,615 | $36K | |
| 80368 | <1% | 3,586 | $36K | |
| 80354 | <1% | 3,559 | $36K | |
| 80324 | <1% | 3,545 | $36K | |
| 80359 | <1% | 3,522 | $35K | |
| 64493 | <1% | 808 | $35K | |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 3,530 | $29K |
| G0483 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed | <1% | 1,802 | $28K |
| J0702 | Injection, betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg | <1% | 4,123 | $27K |
| 80373 | <1% | 2,480 | $26K | |
| 80355 | <1% | 2,451 | $25K | |
| 80372 | <1% | 2,423 | $25K | |
| 80366 | <1% | 2,409 | $25K | |
| 80369 | <1% | 2,400 | $25K | |
| 80345 | <1% | 2,386 | $24K | |
| 97161 | <1% | 515 | $23K | |
| 93922 | <1% | 203 | $19K | |
| 95922 | <1% | 644 | $18K | |
| 96131 | <1% | 302 | $18K | |
| 99215 | Doctor's office visit, returning patient (complex) | <1% | 255 | $17K |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 177 | $14K |
| 96130 | <1% | 795 | $13K | |
| 77002 | <1% | 399 | $13K | |
| 87801 | Infectious agent detection by nucleic acid; amplified probe, multiple organisms | <1% | 118 | $12K |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 848 | $12K |
| 99487 | Ccm add 20min | <1% | 1,193 | $9K |
| L1832 | Knee orthosis, adjustable knee joints (unicentric or polycentric), positional orthosis, rigid support, prefabricated item that has been trimmed, bent, molded, assembled, or otherwise customized to fit a specific patient by an individual with expertise | <1% | 19 | $8K |
| 99489 | Ccm add 20min | <1% | 683 | $7K |
| 64640 | <1% | 45 | $7K | |
| 90833 | Psychotherapy, 30 minutes with patient when performed with an E&M service (add-on) | <1% | 136 | $7K |
| 90791 | Psychiatric diagnostic evaluation | <1% | 99 | $7K |
| 64494 | <1% | 254 | $6K | |
| 64483 | <1% | 110 | $6K | |
| 93040 | <1% | 1,523 | $6K | |
| 80338 | <1% | 535 | $5K | |
| 80335 | <1% | 534 | $5K | |
| 80332 | <1% | 521 | $5K | |
| 64495 | <1% | 163 | $5K | |
| 64484 | <1% | 110 | $5K | |
| 97760 | <1% | 161 | $4K | |
| L0631 | Lumbar-sacral orthosis, sagittal control, with rigid anterior and posterior panels, posterior extends from sacrococcygeal junction to t-9 vertebra, produces intracavitary pressure to reduce load on the intervertebral discs, includes straps, closures, may include padding, shoulder straps, pendulous abdomen design, prefabricated item that has been trimmed, bent, molded, assembled, or otherwise customized to fit a specific patient by an individual with expertise | <1% | 90 | $4K |
| 64635 | <1% | 29 | $4K | |
| 80299 | <1% | 282 | $4K | |
| 80321 | <1% | 245 | $3K | |
| 80320 | <1% | 245 | $3K | |
| 80305 | <1% | 478 | $3K | |
| 72275 | <1% | 79 | $3K | |
| 80342 | <1% | 283 | $3K | |
| 80323 | <1% | 286 | $3K | |
| 98940 | <1% | 224 | $3K | |
| Q9965 | Low osmolar contrast material, 100-199 mg/ml iodine concentration, per ml | <1% | 4,610 | $3K |
| 20553 | <1% | 91 | $3K | |
| 99490 | Ccm add 20min | <1% | 536 | $3K |
| 98941 | Chiropractic manipulative treatment; spinal, 3-4 regions | <1% | 159 | $2K |
| 20610 | <1% | 66 | $2K | |
| 97032 | <1% | 299 | $2K | |
| A4595 | Electrical stimulator supplies, 2 lead, per month, (e.g., tens, nmes) | <1% | 134 | $2K |
| 90837 | Psychotherapy session, about an hour | <1% | 40 | $2K |
| J3490 | Unclassified drugs | <1% | 1,148 | $1K |
| 97012 | <1% | 178 | $1K | |
| G3002 | Chronic pain management and treatment, monthly bundle including, diagnosis; assessment and monitoring; administration of a validated pain rating scale or tool; the development, implementation, revision, and/or maintenance of a person-centered care plan that includes strengths, goals, clinical needs, and desired outcomes; overall treatment management; facilitation and coordination of any necessary behavioral health treatment; medication management; pain and health literacy counseling; any necessary chronic pain related crisis care; and ongoing communication and care coordination between relevant practitioners furnishing care, e.g. physical therapy and occupational therapy, complementary and integrative approaches, and community-based care, as appropriate. required initial face-to-face visit at least 30 minutes provided by a physician or other qualified health professional; first 30 minutes personally provided by physician or other qualified health care professional, per calendar month. (when using g3002, 30 minutes must be met or exceeded.) | <1% | 447 | $1K |
| 96132 | <1% | 72 | $937.20 | |
| 87653 | <1% | 129 | $934.15 | |
| 97535 | Self-care/home management training, each 15 minutes | <1% | 58 | $915.22 |
| 87640 | <1% | 142 | $735.40 | |
| 64636 | <1% | 14 | $723.20 | |
| 87641 | <1% | 126 | $678.27 | |
| 80343 | <1% | 51 | $531.56 | |
| 97750 | <1% | 15 | $483.28 | |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 212 | $405.32 |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 107 | $369.30 |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 151 | $237.84 |
| 80184 | <1% | 2,402 | $216.44 | |
| 99484 | <1% | 48 | $208.50 | |
| 87481 | <1% | 27 | $184.80 | |
| 99439 | <1% | 83 | $182.75 | |
| 99437 | <1% | 44 | $143.52 | |
| J1094 | Injection, dexamethasone acetate, 1 mg | <1% | 1,983 | $123.78 |
| 81002 | <1% | 152 | $121.95 | |
| A4215 | Needle, sterile, any size, each | <1% | 7,994 | $112.08 |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 332 | $106.62 |
| 87500 | <1% | 15 | $105.29 | |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 7,934 | $104.44 |
| 99491 | Ccm add 20min | <1% | 50 | $73.16 |
| 96138 | <1% | 71 | $70.84 | |
| G3003 | Each additional 15 minutes of chronic pain management and treatment by a physician or other qualified health care professional, per calendar month. (list separately in addition to code for g3002. when using g3003, 15 minutes must be met or exceeded.) | <1% | 16 | $41.58 |
| J2795 | Injection, ropivacaine hydrochloride, 1 mg | <1% | 495 | $39.79 |
| 99071 | <1% | 358 | $25.00 | |
| 90901 | <1% | 15 | $22.70 | |
| A4550 | Surgical trays | <1% | 4,812 | $20.40 |
| G2211 | Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's single, serious condition or a complex condition. (add-on code, list separately in addition to office/outpatient evaluation and management visit, new or established) | <1% | 110 | $19.08 |
| S0020 | Injection, bupivicaine hydrochloride, 30 ml | 0% | 534 | $0.00 |
| A4630 | Replacement batteries, medically necessary, transcutaneous electrical stimulator, owned by patient | 0% | 27 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialTAYEB, ZEESHAN (OWNER)